Skip to main content
OpenTrials
Completed

NCT Number: NCT01488747

Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride

The primary objective of this investigation is to determine the relative percentage and rate of incorporation of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total omega-3 (n-3) fatty acids after ingestion of 4 emulsified flavored triglyceride fish oil supplements versus an encapsulated triglyceride in defined plasma lipid pools.

The primary endpoints to be evaluated include the fatty acid composition of plasma lipids before and after consumption of a single dose of emulsified triglyceride based fish oil and triglyceride of similar n-3 compositions in capsule form. The investigators will measure changes in plasma phospholipid, and chylomicron fatty acids.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Adults

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

USDA Grand Forks Human Nutrition Research Center

Grand Forks, North Dakota, 58203, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults ages 18 to 60.
  • Body mass index between 22 and 32 kg/m2.
  • Medical history (interview) demonstrating good health.
  • Nonsmoker.
  • Consumption of a typical American diet with no unusual dietary habits.
  • Willingness to comply with the study protocol.
  • Low reported n-3 intake (<100 mg/d) on the Omega-3 Checklist

Exclusion criteria

  • Any active, uncontrolled medical problem.
  • Consumption of essential fatty acid supplements within the past 6 months.
  • Use of lipid lowering drugs.
  • Fish consumption greater than 1 fish meal per week

Treatment and study plan

Coromega Omega-3 Squeeze

Dietary Supplement

660 mg EPA, 434 mg DHA

Coromega Nectar

Dietary Supplement

660 mg EPA, 436 mg DHA

Barleans Swirl

Dietary Supplement

660 mg EPA, 660 mg DHA

Nordic Omega-3 Softgel

Dietary Supplement

660 mg EPA, 440 mg DHA

Primary outcomes

  1. Area under the curve for phospholipid fatty acids

    Time frame: 48 hours

    Evaluation of the bioavailability of fatty acids from fish oil supplements

Secondary outcomes

  1. Area under the curve for chylomicron fatty acids

    Time frame: 48 hours

    Evaluation of the bioavailability of fatty acids from fish oil supplements

Sponsors and collaborators

Lead sponsor

USDA Grand Forks Human Nutrition Research Center

Fed

Registry information

Official study title

Bioavailability of Fish Oils: Emulsified vs. Capsular Triglyceride

Important dates

Study start
2011
Primary completion
2012
Study completion
2016
First posted
Dec 8, 2011
Registry last updated
Aug 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.